{"transactions":[{"id":4625194,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":183940,"kind":"person","name":"Clark Ronnie Duane","position":1,"cik":"0002155825","reported_name":"Clark Ronnie Duane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2026-09-23T10:05:45.000Z","date":"2026-09-15","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represent an initial award of options in consideration for the Reporting Person's service to the Board of Directors of INmune Bio, Inc. Granted pursuant to the Issuer's Third Amended and Restated 2021 Stock Incentive Plan. The options will vest in 36 equal installments over three (3) years (1/36 per month) beginning one month after the grant date until the option is 100% vested which shall occur on the three-year anniversary of the date of grant."}],"balance_after":100000,"derivative":{"exercise_price":2.33,"expiration_date":"2036-09-14","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001213900-26-102342","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2155825/000121390026102342/ownership.xml","form_type":"4"}},{"id":4620682,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2026-09-17T17:44:11.000Z","date":"2026-09-15","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represent an initial award of options in consideration for the Reporting Person's service to the Board of Directors of INmune Bio, Inc. Granted pursuant to the Issuer's Third Amended and Restated 2021 Stock Incentive Plan. The options will vest in 36 equal installments over three (3) years (1/36 per month) beginning one month after the grant date until the option is 100% vested which shall occur on the three-year anniversary of the date of grant."}],"balance_after":100000,"derivative":{"exercise_price":2.33,"expiration_date":"2036-09-14","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001213900-26-100877","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026100877/ownership.xml","form_type":"4"}},{"id":713360,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Purchase Warrant","published_at":"2026-07-07T11:01:50.000Z","date":"2026-07-02","kind":"other","planned":false,"acquired":false,"shares":14801,"price":0.125,"value":1850.125,"ownership":{"direct":true},"balance_after":14802,"derivative":{"exercise_price":1.4,"exercise_date":"2026-07-02","expiration_date":"2027-12-31","underlying":"Common Stock","underlying_shares":14801},"source":{"system":"sec-edgar","filing":"0001213900-26-075738","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026075738/ownership.xml","form_type":"4"}},{"id":713359,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-07T11:01:50.000Z","date":"2026-07-02","kind":"exercise","planned":false,"acquired":true,"shares":14801,"price":1.4,"value":20721.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 14,801 shares of Common Stock acquired upon exercise of common stock purchase warrants held by the Reporting Person. The Reporting Person and other holders of common stock purchase warrants previously issued by the Issuer in its April 2024 offerings on April 24, 2024 and April 29, 2024, as such warrants were amended on December 22, 2025 (the \"April 2024 Warrants\"), entered into a warrant inducement offer letter agreement with the Issuer (the \"Inducement Letter\"). Pursuant to the Inducement Letter, the Reporting Person agreed to exercise, for cash, 14,801 April 2024 Warrants, representing 50% of the April 2024 Warrants held by it, and agreed to purchase 14,801 shares of common stock at a reduced exercise price of $1.40 in exchange for the Issuer's agreement to extend the maturity date of the April 2024 Warrants, as it relates to the remaining 50% of the April 2024 Warrants that were not exercised, from June 30, 2026, to December 31, 2027."}],"balance_after":86404,"source":{"system":"sec-edgar","filing":"0001213900-26-075738","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026075738/ownership.xml","form_type":"4"}},{"id":713358,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31620,"kind":"person","name":"Lowdell Mark William","position":1,"cik":"0001767037","reported_name":"Lowdell Mark William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock Purchase Warrant","published_at":"2026-07-07T11:01:16.000Z","date":"2026-07-02","kind":"other","planned":false,"acquired":false,"shares":7211,"price":0.125,"value":901.375,"ownership":{"direct":true},"balance_after":7212,"derivative":{"exercise_price":1.4,"exercise_date":"2026-07-02","expiration_date":"2027-12-31","underlying":"Common Stock","underlying_shares":7211},"source":{"system":"sec-edgar","filing":"0001213900-26-075737","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026075737/ownership.xml","form_type":"4"}},{"id":713357,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31620,"kind":"person","name":"Lowdell Mark William","position":1,"cik":"0001767037","reported_name":"Lowdell Mark William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-07-07T11:01:16.000Z","date":"2026-07-02","kind":"exercise","planned":false,"acquired":true,"shares":7211,"price":1.4,"value":10095.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 7,211 shares of Common Stock acquired upon exercise of common stock purchase warrants held by the Reporting Person. The Reporting Person and other holders of common stock purchase warrants previously issued by the Issuer in its April 2024 offerings on April 24, 2024 and April 29, 2024, as such warrants were amended on December 22, 2025 (the \"April 2024 Warrants\"), entered into a warrant inducement offer letter agreement with the Issuer (the \"Inducement Letter\"). Pursuant to the Inducement Letter, the Reporting Person agreed to exercise, for cash, 7,211 April 2024 Warrants, representing 50% of the April 2024 Warrants held by it, and agreed to purchase 7,211 shares of common stock at a reduced exercise price of $1.40 in exchange for the Issuer's agreement to extend the maturity date of the April 2024 Warrants, as it relates to the remaining 50% of the April 2024 Warrants that were not exercised, from June 30, 2026, to December 31, 2027."}],"balance_after":1518017,"source":{"system":"sec-edgar","filing":"0001213900-26-075737","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026075737/ownership.xml","form_type":"4"}},{"id":713531,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31673,"kind":"person","name":"Moss David J","position":1,"cik":"0001421930","reported_name":"Moss David J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock Purchase Warrant","published_at":"2026-07-07T07:00:35.000Z","date":"2026-07-02","kind":"other","planned":false,"acquired":false,"shares":9014,"price":0.125,"value":1126.75,"ownership":{"direct":true},"balance_after":9014,"derivative":{"exercise_price":1.4,"exercise_date":"2026-07-02","expiration_date":"2027-12-31","underlying":"Common Stock","underlying_shares":9014},"source":{"system":"sec-edgar","filing":"0001213900-26-075736","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1421930/000121390026075736/ownership.xml","form_type":"4"}},{"id":713530,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31673,"kind":"person","name":"Moss David J","position":1,"cik":"0001421930","reported_name":"Moss David J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-07T07:00:35.000Z","date":"2026-07-02","kind":"exercise","planned":false,"acquired":true,"shares":9014,"price":1.4,"value":12619.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 9,014 shares of Common Stock acquired upon exercise of common stock purchase warrants held by the Reporting Person. The Reporting Person and other holders of common stock purchase warrants previously issued by the Issuer in its April 2024 offerings on April 24, 2024 and April 29, 2024, as such warrants were amended on December 22, 2025 (the \"April 2024 Warrants\"), entered into a warrant inducement offer letter agreement with the Issuer (the \"Inducement Letter\"). Pursuant to the Inducement Letter, the Reporting Person agreed to exercise, for cash, 9,014 April 2024 Warrants, representing 50% of the April 2024 Warrants held by it, and agreed to purchase 9,014 shares of common stock at a reduced exercise price of $1.40 in exchange for the Issuer's agreement to extend the maturity date of the April 2024 Warrants, as it relates to the remaining 50% of the April 2024 Warrants that were not exercised, from June 30, 2026, to December 31, 2027."}],"balance_after":1294883,"source":{"system":"sec-edgar","filing":"0001213900-26-075736","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1421930/000121390026075736/ownership.xml","form_type":"4"}},{"id":983166,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31620,"kind":"person","name":"Lowdell Mark William","position":1,"cik":"0001767037","reported_name":"Lowdell Mark William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Option (right to buy)","published_at":"2025-12-02T21:43:26.000Z","date":"2025-12-01","kind":"grant","planned":false,"acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Granted pursuant to the Issuer's Second Amended and Restated 2021 Stock Incentive Plan. One-fourth (1/4) of the option will vest 12 months from the date of grant and thereafter the remaining unvested option will become vested and exercisable pro rata on a monthly basis over three (3) years (1/36 per month) until the option is 100% vested which shall occur on the four-year anniversary of the date of grant."}],"balance_after":600000,"derivative":{"exercise_price":1.48,"expiration_date":"2035-11-23","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001213900-25-117309","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025117309/ownership.xml","form_type":"4"}},{"id":983165,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2025-12-02T21:41:42.000Z","date":"2025-12-01","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Granted pursuant to the Issuer's Second Amended and Restated 2021 Stock Incentive Plan. The option will become vested and exercisable pro rata on a monthly basis over three (3) years (1/36 per month) until the option is 100% vested, which shall occur on the three-year anniversary of the date of grant."}],"balance_after":150000,"derivative":{"exercise_price":1.48,"expiration_date":"2035-11-23","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001213900-25-117305","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025117305/ownership.xml","form_type":"4"}},{"id":983164,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2025-12-02T21:40:56.000Z","date":"2025-12-01","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Granted pursuant to the Issuer's Second Amended and Restated 2021 Stock Incentive Plan. The option will become vested and exercisable pro rata on a monthly basis over three (3) years (1/36 per month) until the option is 100% vested, which shall occur on the three-year anniversary of the date of grant."}],"balance_after":150000,"derivative":{"exercise_price":1.48,"expiration_date":"2035-11-23","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001213900-25-117303","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025117303/ownership.xml","form_type":"4"}},{"id":983163,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72353,"kind":"person","name":"Ganjei James Kelly","position":1,"cik":"0001767300","reported_name":"Ganjei James Kelly","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2025-12-02T21:39:41.000Z","date":"2025-12-01","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Granted pursuant to the Issuer's Second Amended and Restated 2021 Stock Incentive Plan. The option will become vested and exercisable pro rata on a monthly basis over three (3) years (1/36 per month) until the option is 100% vested, which shall occur on the three-year anniversary of the date of grant."}],"balance_after":150000,"derivative":{"exercise_price":1.48,"expiration_date":"2035-11-23","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001213900-25-117302","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025117302/ownership.xml","form_type":"4"}},{"id":983474,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31673,"kind":"person","name":"Moss David J","position":1,"cik":"0001421930","reported_name":"Moss David J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option (right to buy)","published_at":"2025-12-02T16:44:20.000Z","date":"2025-12-01","kind":"grant","planned":false,"acquired":true,"shares":750000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Granted pursuant to the Issuer's Second Amended and Restated 2021 Stock Incentive Plan. One-fourth (1/4) of the option will vest 12 months from the date of grant and thereafter the remaining unvested option will become vested and exercisable pro rata on a monthly basis over three (3) years (1/36 per month) until the option is 100% vested which shall occur on the four-year anniversary of the date of grant."}],"balance_after":750000,"derivative":{"exercise_price":1.48,"expiration_date":"2035-11-23","underlying":"Common Stock","underlying_shares":750000},"source":{"system":"sec-edgar","filing":"0001213900-25-117311","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1421930/000121390025117311/ownership.xml","form_type":"4"}},{"id":983964,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72373,"kind":"person","name":"Ellspermann Cory Randall","position":1,"cik":"0002082083","reported_name":"Ellspermann Cory Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Option (right to buy)","published_at":"2025-12-02T16:42:26.000Z","date":"2025-12-01","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Granted pursuant to the Issuer's Second Amended and Restated 2021 Stock Incentive Plan. One-fourth (1/4) of the option will vest 12 months from the date of grant and thereafter the remaining unvested option will become vested and exercisable pro rata on a monthly basis over three (3) years (1/36 per month) until the option is 100% vested which shall occur on the four-year anniversary of the date of grant."}],"balance_after":300000,"derivative":{"exercise_price":1.48,"expiration_date":"2035-11-23","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001213900-25-117306","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2082083/000121390025117306/ownership.xml","form_type":"4"}},{"id":984040,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72384,"kind":"person","name":"ALLEN MARCIA","position":1,"cik":"0001109769","reported_name":"ALLEN MARCIA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2025-12-02T16:38:42.000Z","date":"2025-12-01","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Granted pursuant to the Issuer's Second Amended and Restated 2021 Stock Incentive Plan. The option will become vested and exercisable pro rata on a monthly basis over three (3) years (1/36 per month) until the option is 100% vested, which shall occur on the three-year anniversary of the date of grant."}],"balance_after":150000,"derivative":{"exercise_price":1.48,"expiration_date":"2035-11-23","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001213900-25-117300","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1109769/000121390025117300/ownership.xml","form_type":"4"}},{"id":995092,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:31:54.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":12500,"derivative":{"exercise_price":1.5,"expiration_date":"2034-05-13","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001213900-25-112241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112241/ownership.xml","form_type":"4"}},{"id":995091,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:31:54.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":9.92,"expiration_date":"2034-05-13","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001213900-25-112241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112241/ownership.xml","form_type":"4"}},{"id":995090,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:31:54.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":32500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":32500,"derivative":{"exercise_price":1.5,"expiration_date":"2034-12-04","underlying":"Common Stock","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0001213900-25-112241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112241/ownership.xml","form_type":"4"}},{"id":995089,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:31:54.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":32500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":5.05,"expiration_date":"2034-12-04","underlying":"Common Stock","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0001213900-25-112241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112241/ownership.xml","form_type":"4"}},{"id":995088,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:31:54.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":35000,"derivative":{"exercise_price":1.5,"expiration_date":"2033-02-15","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001213900-25-112241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112241/ownership.xml","form_type":"4"}},{"id":995087,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:31:54.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":9.74,"expiration_date":"2033-02-15","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001213900-25-112241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112241/ownership.xml","form_type":"4"}},{"id":995086,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:31:54.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":35000,"derivative":{"exercise_price":1.5,"expiration_date":"2032-03-20","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001213900-25-112241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112241/ownership.xml","form_type":"4"}},{"id":995085,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:31:54.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":7.92,"expiration_date":"2032-03-20","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001213900-25-112241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112241/ownership.xml","form_type":"4"}},{"id":995084,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:31:54.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":19025,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":19025,"derivative":{"exercise_price":1.5,"expiration_date":"2031-06-21","underlying":"Common Stock","underlying_shares":19025},"source":{"system":"sec-edgar","filing":"0001213900-25-112241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112241/ownership.xml","form_type":"4"}},{"id":995083,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:31:54.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19025,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":17.49,"expiration_date":"2031-06-21","underlying":"Common Stock","underlying_shares":19025},"source":{"system":"sec-edgar","filing":"0001213900-25-112241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112241/ownership.xml","form_type":"4"}},{"id":995082,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:31:54.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":15975,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":15975,"derivative":{"exercise_price":1.5,"expiration_date":"2031-01-18","underlying":"Common Stock","underlying_shares":15975},"source":{"system":"sec-edgar","filing":"0001213900-25-112241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112241/ownership.xml","form_type":"4"}},{"id":995081,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:31:54.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15975,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":24.82,"expiration_date":"2031-01-18","underlying":"Common Stock","underlying_shares":15975},"source":{"system":"sec-edgar","filing":"0001213900-25-112241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112241/ownership.xml","form_type":"4"}},{"id":995080,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:31:54.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":108000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":108000,"derivative":{"exercise_price":1.5,"expiration_date":"2029-11-24","underlying":"Common Stock","underlying_shares":108000},"source":{"system":"sec-edgar","filing":"0001213900-25-112241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112241/ownership.xml","form_type":"4"}},{"id":995079,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:31:54.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":108000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":3.91,"expiration_date":"2029-11-24","underlying":"Common Stock","underlying_shares":108000},"source":{"system":"sec-edgar","filing":"0001213900-25-112241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112241/ownership.xml","form_type":"4"}},{"id":995078,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:31:54.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":108000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":108000,"derivative":{"exercise_price":1.5,"expiration_date":"2028-04-01","underlying":"Common Stock","underlying_shares":108000},"source":{"system":"sec-edgar","filing":"0001213900-25-112241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112241/ownership.xml","form_type":"4"}},{"id":995077,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:31:54.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":108000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":7.8,"expiration_date":"2028-04-01","underlying":"Common Stock","underlying_shares":108000},"source":{"system":"sec-edgar","filing":"0001213900-25-112241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112241/ownership.xml","form_type":"4"}},{"id":995076,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31620,"kind":"person","name":"Lowdell Mark William","position":1,"cik":"0001767037","reported_name":"Lowdell Mark William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:29:25.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":100000,"derivative":{"exercise_price":1.5,"expiration_date":"2034-05-13","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001213900-25-112236","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112236/ownership.xml","form_type":"4"}},{"id":995075,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31620,"kind":"person","name":"Lowdell Mark William","position":1,"cik":"0001767037","reported_name":"Lowdell Mark William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:29:25.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":9.92,"expiration_date":"2034-05-13","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001213900-25-112236","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112236/ownership.xml","form_type":"4"}},{"id":995074,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31620,"kind":"person","name":"Lowdell Mark William","position":1,"cik":"0001767037","reported_name":"Lowdell Mark William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:29:25.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":140000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":140000,"derivative":{"exercise_price":1.5,"expiration_date":"2034-12-04","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001213900-25-112236","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112236/ownership.xml","form_type":"4"}},{"id":995073,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31620,"kind":"person","name":"Lowdell Mark William","position":1,"cik":"0001767037","reported_name":"Lowdell Mark William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:29:25.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":140000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":5.05,"expiration_date":"2034-12-04","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001213900-25-112236","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112236/ownership.xml","form_type":"4"}},{"id":995072,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31620,"kind":"person","name":"Lowdell Mark William","position":1,"cik":"0001767037","reported_name":"Lowdell Mark William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:29:25.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":104000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":104000,"derivative":{"exercise_price":1.5,"expiration_date":"2032-03-20","underlying":"Common Stock","underlying_shares":104000},"source":{"system":"sec-edgar","filing":"0001213900-25-112236","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112236/ownership.xml","form_type":"4"}},{"id":995071,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31620,"kind":"person","name":"Lowdell Mark William","position":1,"cik":"0001767037","reported_name":"Lowdell Mark William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:29:25.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":104000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":7.92,"expiration_date":"2032-03-20","underlying":"Common Stock","underlying_shares":104000},"source":{"system":"sec-edgar","filing":"0001213900-25-112236","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112236/ownership.xml","form_type":"4"}},{"id":995070,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31620,"kind":"person","name":"Lowdell Mark William","position":1,"cik":"0001767037","reported_name":"Lowdell Mark William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:29:25.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":180000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":180000,"derivative":{"exercise_price":1.5,"expiration_date":"2029-11-24","underlying":"Common Stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0001213900-25-112236","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112236/ownership.xml","form_type":"4"}},{"id":995069,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31620,"kind":"person","name":"Lowdell Mark William","position":1,"cik":"0001767037","reported_name":"Lowdell Mark William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:29:25.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":180000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":3.91,"expiration_date":"2029-11-24","underlying":"Common Stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0001213900-25-112236","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112236/ownership.xml","form_type":"4"}},{"id":995068,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31620,"kind":"person","name":"Lowdell Mark William","position":1,"cik":"0001767037","reported_name":"Lowdell Mark William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:29:25.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":400000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":400000,"derivative":{"exercise_price":1.5,"expiration_date":"2028-01-01","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001213900-25-112236","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112236/ownership.xml","form_type":"4"}},{"id":995067,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31620,"kind":"person","name":"Lowdell Mark William","position":1,"cik":"0001767037","reported_name":"Lowdell Mark William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:29:25.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":400000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":7.8,"expiration_date":"2028-01-01","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001213900-25-112236","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112236/ownership.xml","form_type":"4"}},{"id":995050,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:27:48.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":12500,"derivative":{"exercise_price":1.5,"expiration_date":"2034-05-13","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001213900-25-112232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112232/ownership.xml","form_type":"4"}},{"id":995049,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:27:48.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":9.92,"expiration_date":"2034-05-13","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001213900-25-112232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112232/ownership.xml","form_type":"4"}},{"id":995048,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:27:48.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":32500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":32500,"derivative":{"exercise_price":1.5,"expiration_date":"2034-12-04","underlying":"Common Stock","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0001213900-25-112232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112232/ownership.xml","form_type":"4"}},{"id":995047,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:27:48.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":32500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":5.05,"expiration_date":"2034-12-04","underlying":"Common Stock","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0001213900-25-112232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112232/ownership.xml","form_type":"4"}},{"id":995046,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:27:48.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":35000,"derivative":{"exercise_price":1.5,"expiration_date":"2033-02-15","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001213900-25-112232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112232/ownership.xml","form_type":"4"}},{"id":995045,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:27:48.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":9.74,"expiration_date":"2033-02-15","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001213900-25-112232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112232/ownership.xml","form_type":"4"}},{"id":995044,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:27:48.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":35000,"derivative":{"exercise_price":1.5,"expiration_date":"2032-03-20","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001213900-25-112232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112232/ownership.xml","form_type":"4"}},{"id":995043,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:27:48.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":7.92,"expiration_date":"2032-03-20","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001213900-25-112232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112232/ownership.xml","form_type":"4"}},{"id":995042,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:27:48.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":19025,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":19025,"derivative":{"exercise_price":1.5,"expiration_date":"2031-06-21","underlying":"Common Stock","underlying_shares":19025},"source":{"system":"sec-edgar","filing":"0001213900-25-112232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112232/ownership.xml","form_type":"4"}},{"id":995041,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:27:48.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19025,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":17.49,"expiration_date":"2031-06-21","underlying":"Common Stock","underlying_shares":19025},"source":{"system":"sec-edgar","filing":"0001213900-25-112232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112232/ownership.xml","form_type":"4"}},{"id":995040,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:27:48.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":15975,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":15975,"derivative":{"exercise_price":1.5,"expiration_date":"2031-01-18","underlying":"Common Stock","underlying_shares":15975},"source":{"system":"sec-edgar","filing":"0001213900-25-112232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112232/ownership.xml","form_type":"4"}},{"id":995039,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:27:48.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15975,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":24.82,"expiration_date":"2031-01-18","underlying":"Common Stock","underlying_shares":15975},"source":{"system":"sec-edgar","filing":"0001213900-25-112232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112232/ownership.xml","form_type":"4"}},{"id":995038,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:27:48.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":108000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":108000,"derivative":{"exercise_price":1.5,"expiration_date":"2029-11-24","underlying":"Common Stock","underlying_shares":108000},"source":{"system":"sec-edgar","filing":"0001213900-25-112232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112232/ownership.xml","form_type":"4"}},{"id":995037,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:27:48.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":108000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":3.91,"expiration_date":"2029-11-24","underlying":"Common Stock","underlying_shares":108000},"source":{"system":"sec-edgar","filing":"0001213900-25-112232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112232/ownership.xml","form_type":"4"}},{"id":995036,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:27:48.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":108000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":108000,"derivative":{"exercise_price":1.5,"expiration_date":"2028-04-01","underlying":"Common Stock","underlying_shares":108000},"source":{"system":"sec-edgar","filing":"0001213900-25-112232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112232/ownership.xml","form_type":"4"}},{"id":995035,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:27:48.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":108000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":7.8,"expiration_date":"2028-04-01","underlying":"Common Stock","underlying_shares":108000},"source":{"system":"sec-edgar","filing":"0001213900-25-112232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112232/ownership.xml","form_type":"4"}},{"id":995066,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72353,"kind":"person","name":"Ganjei James Kelly","position":1,"cik":"0001767300","reported_name":"Ganjei James Kelly","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:26:52.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":12500,"derivative":{"exercise_price":1.5,"expiration_date":"2034-05-13","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001213900-25-112229","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112229/ownership.xml","form_type":"4"}},{"id":995065,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72353,"kind":"person","name":"Ganjei James Kelly","position":1,"cik":"0001767300","reported_name":"Ganjei James Kelly","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:26:52.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":9.92,"expiration_date":"2034-05-13","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001213900-25-112229","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112229/ownership.xml","form_type":"4"}},{"id":995064,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72353,"kind":"person","name":"Ganjei James Kelly","position":1,"cik":"0001767300","reported_name":"Ganjei James Kelly","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:26:52.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":32500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":32500,"derivative":{"exercise_price":1.5,"expiration_date":"2034-12-04","underlying":"Common Stock","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0001213900-25-112229","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112229/ownership.xml","form_type":"4"}},{"id":995063,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72353,"kind":"person","name":"Ganjei James Kelly","position":1,"cik":"0001767300","reported_name":"Ganjei James Kelly","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:26:52.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":32500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":5.05,"expiration_date":"2034-12-04","underlying":"Common Stock","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0001213900-25-112229","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112229/ownership.xml","form_type":"4"}},{"id":995062,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72353,"kind":"person","name":"Ganjei James Kelly","position":1,"cik":"0001767300","reported_name":"Ganjei James Kelly","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:26:52.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":35000,"derivative":{"exercise_price":1.5,"expiration_date":"2033-02-15","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001213900-25-112229","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112229/ownership.xml","form_type":"4"}},{"id":995061,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72353,"kind":"person","name":"Ganjei James Kelly","position":1,"cik":"0001767300","reported_name":"Ganjei James Kelly","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:26:52.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":9.74,"expiration_date":"2033-02-15","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001213900-25-112229","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112229/ownership.xml","form_type":"4"}},{"id":995060,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72353,"kind":"person","name":"Ganjei James Kelly","position":1,"cik":"0001767300","reported_name":"Ganjei James Kelly","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:26:52.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":35000,"derivative":{"exercise_price":1.5,"expiration_date":"2032-03-20","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001213900-25-112229","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112229/ownership.xml","form_type":"4"}},{"id":995059,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72353,"kind":"person","name":"Ganjei James Kelly","position":1,"cik":"0001767300","reported_name":"Ganjei James Kelly","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:26:52.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":7.92,"expiration_date":"2032-03-20","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001213900-25-112229","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112229/ownership.xml","form_type":"4"}},{"id":995058,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72353,"kind":"person","name":"Ganjei James Kelly","position":1,"cik":"0001767300","reported_name":"Ganjei James Kelly","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:26:52.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":19025,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":19025,"derivative":{"exercise_price":1.5,"expiration_date":"2031-06-21","underlying":"Common Stock","underlying_shares":19025},"source":{"system":"sec-edgar","filing":"0001213900-25-112229","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112229/ownership.xml","form_type":"4"}},{"id":995057,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72353,"kind":"person","name":"Ganjei James Kelly","position":1,"cik":"0001767300","reported_name":"Ganjei James Kelly","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:26:52.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19025,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":17.49,"expiration_date":"2031-06-21","underlying":"Common Stock","underlying_shares":19025},"source":{"system":"sec-edgar","filing":"0001213900-25-112229","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112229/ownership.xml","form_type":"4"}},{"id":995056,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72353,"kind":"person","name":"Ganjei James Kelly","position":1,"cik":"0001767300","reported_name":"Ganjei James Kelly","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:26:52.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":15975,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":15975,"derivative":{"exercise_price":1.5,"expiration_date":"2031-01-18","underlying":"Common Stock","underlying_shares":15975},"source":{"system":"sec-edgar","filing":"0001213900-25-112229","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112229/ownership.xml","form_type":"4"}},{"id":995055,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72353,"kind":"person","name":"Ganjei James Kelly","position":1,"cik":"0001767300","reported_name":"Ganjei James Kelly","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:26:52.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15975,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":24.82,"expiration_date":"2031-01-18","underlying":"Common Stock","underlying_shares":15975},"source":{"system":"sec-edgar","filing":"0001213900-25-112229","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112229/ownership.xml","form_type":"4"}},{"id":995054,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72353,"kind":"person","name":"Ganjei James Kelly","position":1,"cik":"0001767300","reported_name":"Ganjei James Kelly","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:26:52.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":108000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":108000,"derivative":{"exercise_price":1.5,"expiration_date":"2029-11-24","underlying":"Common Stock","underlying_shares":108000},"source":{"system":"sec-edgar","filing":"0001213900-25-112229","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112229/ownership.xml","form_type":"4"}},{"id":995053,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72353,"kind":"person","name":"Ganjei James Kelly","position":1,"cik":"0001767300","reported_name":"Ganjei James Kelly","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:26:52.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":108000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":3.91,"expiration_date":"2029-11-24","underlying":"Common Stock","underlying_shares":108000},"source":{"system":"sec-edgar","filing":"0001213900-25-112229","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112229/ownership.xml","form_type":"4"}},{"id":995052,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72353,"kind":"person","name":"Ganjei James Kelly","position":1,"cik":"0001767300","reported_name":"Ganjei James Kelly","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:26:52.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":108000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":108000,"derivative":{"exercise_price":1.5,"expiration_date":"2028-04-01","underlying":"Common Stock","underlying_shares":108000},"source":{"system":"sec-edgar","filing":"0001213900-25-112229","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112229/ownership.xml","form_type":"4"}},{"id":995051,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72353,"kind":"person","name":"Ganjei James Kelly","position":1,"cik":"0001767300","reported_name":"Ganjei James Kelly","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:26:52.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":108000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":7.8,"expiration_date":"2028-04-01","underlying":"Common Stock","underlying_shares":108000},"source":{"system":"sec-edgar","filing":"0001213900-25-112229","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112229/ownership.xml","form_type":"4"}},{"id":995549,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31673,"kind":"person","name":"Moss David J","position":1,"cik":"0001421930","reported_name":"Moss David J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T17:31:03.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":160000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":160000,"derivative":{"exercise_price":1.5,"expiration_date":"2034-05-13","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001213900-25-112239","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1421930/000121390025112239/ownership.xml","form_type":"4"}},{"id":995548,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31673,"kind":"person","name":"Moss David J","position":1,"cik":"0001421930","reported_name":"Moss David J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T17:31:03.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":160000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":9.92,"expiration_date":"2034-05-13","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001213900-25-112239","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1421930/000121390025112239/ownership.xml","form_type":"4"}},{"id":995547,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31673,"kind":"person","name":"Moss David J","position":1,"cik":"0001421930","reported_name":"Moss David J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T17:31:03.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":223000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":223000,"derivative":{"exercise_price":1.5,"expiration_date":"2034-12-04","underlying":"Common Stock","underlying_shares":223000},"source":{"system":"sec-edgar","filing":"0001213900-25-112239","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1421930/000121390025112239/ownership.xml","form_type":"4"}},{"id":995546,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31673,"kind":"person","name":"Moss David J","position":1,"cik":"0001421930","reported_name":"Moss David J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T17:31:03.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":223000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":5.05,"expiration_date":"2034-12-04","underlying":"Common Stock","underlying_shares":223000},"source":{"system":"sec-edgar","filing":"0001213900-25-112239","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1421930/000121390025112239/ownership.xml","form_type":"4"}},{"id":995545,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31673,"kind":"person","name":"Moss David J","position":1,"cik":"0001421930","reported_name":"Moss David J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T17:31:03.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":130000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":130000,"derivative":{"exercise_price":1.5,"expiration_date":"2032-03-20","underlying":"Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0001213900-25-112239","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1421930/000121390025112239/ownership.xml","form_type":"4"}},{"id":995544,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31673,"kind":"person","name":"Moss David J","position":1,"cik":"0001421930","reported_name":"Moss David J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T17:31:03.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":130000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":7.92,"expiration_date":"2032-03-20","underlying":"Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0001213900-25-112239","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1421930/000121390025112239/ownership.xml","form_type":"4"}},{"id":995543,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31673,"kind":"person","name":"Moss David J","position":1,"cik":"0001421930","reported_name":"Moss David J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T17:31:03.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":160000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":160000,"derivative":{"exercise_price":1.5,"expiration_date":"2033-02-15","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001213900-25-112239","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1421930/000121390025112239/ownership.xml","form_type":"4"}},{"id":995542,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31673,"kind":"person","name":"Moss David J","position":1,"cik":"0001421930","reported_name":"Moss David J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T17:31:03.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":160000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":9.74,"expiration_date":"2033-02-15","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001213900-25-112239","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1421930/000121390025112239/ownership.xml","form_type":"4"}},{"id":995541,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31673,"kind":"person","name":"Moss David J","position":1,"cik":"0001421930","reported_name":"Moss David J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T17:31:03.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":70663,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":70663,"derivative":{"exercise_price":1.5,"expiration_date":"2031-06-21","underlying":"Common Stock","underlying_shares":70663},"source":{"system":"sec-edgar","filing":"0001213900-25-112239","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1421930/000121390025112239/ownership.xml","form_type":"4"}},{"id":995540,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31673,"kind":"person","name":"Moss David J","position":1,"cik":"0001421930","reported_name":"Moss David J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T17:31:03.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":70663,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":17.49,"expiration_date":"2031-06-21","underlying":"Common Stock","underlying_shares":70663},"source":{"system":"sec-edgar","filing":"0001213900-25-112239","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1421930/000121390025112239/ownership.xml","form_type":"4"}},{"id":995539,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31673,"kind":"person","name":"Moss David J","position":1,"cik":"0001421930","reported_name":"Moss David J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T17:31:03.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":275000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":275000,"derivative":{"exercise_price":1.5,"expiration_date":"2029-11-24","underlying":"Common Stock","underlying_shares":275000},"source":{"system":"sec-edgar","filing":"0001213900-25-112239","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1421930/000121390025112239/ownership.xml","form_type":"4"}},{"id":995538,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31673,"kind":"person","name":"Moss David J","position":1,"cik":"0001421930","reported_name":"Moss David J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T17:31:03.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":275000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":3.91,"expiration_date":"2029-11-24","underlying":"Common Stock","underlying_shares":275000},"source":{"system":"sec-edgar","filing":"0001213900-25-112239","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1421930/000121390025112239/ownership.xml","form_type":"4"}},{"id":995537,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31673,"kind":"person","name":"Moss David J","position":1,"cik":"0001421930","reported_name":"Moss David J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T17:31:03.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":59337,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":59337,"derivative":{"exercise_price":1.5,"expiration_date":"2031-01-18","underlying":"Common Stock","underlying_shares":59337},"source":{"system":"sec-edgar","filing":"0001213900-25-112239","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1421930/000121390025112239/ownership.xml","form_type":"4"}},{"id":995536,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31673,"kind":"person","name":"Moss David J","position":1,"cik":"0001421930","reported_name":"Moss David J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T17:31:03.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":59337,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":24.82,"expiration_date":"2031-01-18","underlying":"Common Stock","underlying_shares":59337},"source":{"system":"sec-edgar","filing":"0001213900-25-112239","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1421930/000121390025112239/ownership.xml","form_type":"4"}},{"id":995535,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31673,"kind":"person","name":"Moss David J","position":1,"cik":"0001421930","reported_name":"Moss David J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T17:31:03.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":400000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":400000,"derivative":{"exercise_price":1.5,"expiration_date":"2028-01-01","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001213900-25-112239","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1421930/000121390025112239/ownership.xml","form_type":"4"}},{"id":995534,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31673,"kind":"person","name":"Moss David J","position":1,"cik":"0001421930","reported_name":"Moss David J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T17:31:03.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":400000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":7.8,"expiration_date":"2028-01-01","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001213900-25-112239","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1421930/000121390025112239/ownership.xml","form_type":"4"}},{"id":996253,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72373,"kind":"person","name":"Ellspermann Cory Randall","position":1,"cik":"0002082083","reported_name":"Ellspermann Cory Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T17:25:54.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":30000,"derivative":{"exercise_price":1.5,"expiration_date":"2034-05-13","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001213900-25-112227","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/2082083/000121390025112227/ownership.xml","form_type":"4"}},{"id":996252,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72373,"kind":"person","name":"Ellspermann Cory Randall","position":1,"cik":"0002082083","reported_name":"Ellspermann Cory Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T17:25:54.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":9.92,"expiration_date":"2034-05-13","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001213900-25-112227","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/2082083/000121390025112227/ownership.xml","form_type":"4"}},{"id":996251,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72373,"kind":"person","name":"Ellspermann Cory Randall","position":1,"cik":"0002082083","reported_name":"Ellspermann Cory Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T17:25:54.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":70000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":70000,"derivative":{"exercise_price":1.5,"expiration_date":"2034-12-04","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001213900-25-112227","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2082083/000121390025112227/ownership.xml","form_type":"4"}},{"id":996250,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72373,"kind":"person","name":"Ellspermann Cory Randall","position":1,"cik":"0002082083","reported_name":"Ellspermann Cory Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T17:25:54.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":70000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":5.05,"expiration_date":"2034-12-04","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001213900-25-112227","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2082083/000121390025112227/ownership.xml","form_type":"4"}},{"id":996249,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72373,"kind":"person","name":"Ellspermann Cory Randall","position":1,"cik":"0002082083","reported_name":"Ellspermann Cory Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T17:25:54.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":30000,"derivative":{"exercise_price":1.5,"expiration_date":"2032-03-20","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001213900-25-112227","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2082083/000121390025112227/ownership.xml","form_type":"4"}},{"id":996248,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72373,"kind":"person","name":"Ellspermann Cory Randall","position":1,"cik":"0002082083","reported_name":"Ellspermann Cory Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T17:25:54.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":7.92,"expiration_date":"2032-03-20","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001213900-25-112227","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2082083/000121390025112227/ownership.xml","form_type":"4"}},{"id":996247,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72373,"kind":"person","name":"Ellspermann Cory Randall","position":1,"cik":"0002082083","reported_name":"Ellspermann Cory Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T17:25:54.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.5,"expiration_date":"2031-07-22","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001213900-25-112227","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2082083/000121390025112227/ownership.xml","form_type":"4"}},{"id":996246,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72373,"kind":"person","name":"Ellspermann Cory Randall","position":1,"cik":"0002082083","reported_name":"Ellspermann Cory Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T17:25:54.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":21.06,"expiration_date":"2031-07-22","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001213900-25-112227","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2082083/000121390025112227/ownership.xml","form_type":"4"}},{"id":996245,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72373,"kind":"person","name":"Ellspermann Cory Randall","position":1,"cik":"0002082083","reported_name":"Ellspermann Cory Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T17:25:54.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":75000,"derivative":{"exercise_price":1.5,"expiration_date":"2029-11-24","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001213900-25-112227","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2082083/000121390025112227/ownership.xml","form_type":"4"}},{"id":996244,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72373,"kind":"person","name":"Ellspermann Cory Randall","position":1,"cik":"0002082083","reported_name":"Ellspermann Cory Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T17:25:54.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":3.91,"expiration_date":"2029-11-24","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001213900-25-112227","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2082083/000121390025112227/ownership.xml","form_type":"4"}},{"id":996319,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72384,"kind":"person","name":"ALLEN MARCIA","position":1,"cik":"0001109769","reported_name":"ALLEN MARCIA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T17:24:55.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":12500,"derivative":{"exercise_price":1.5,"expiration_date":"2034-05-13","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001213900-25-112223","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1109769/000121390025112223/ownership.xml","form_type":"4"}}],"next_cursor":"2025-11-18T17:24:55.000000Z,996319"}